Table 1.
Most relevant miRNAs in cancer
| miRNA | Tumor | Main target genes | Function | Reference |
|---|---|---|---|---|
| miR-15a | Multiple Myeloma | BCL2, MYB, MYC, KRAS, CCND1, CDC25A, ERBB2, TP53, PTEN, ITGA2, VEGFA,RAB21, CADM1, DICER1 | Oncogene Inhibition, Cell Cycle Control, Inhibition of Angiogenesis | [97-100] |
| miR-34a | Breast, Prostate, Bladder, and Brain Cancer | BCL2, MYC, MET, MEK1, E2F3, CDK4, CDK6, CD44 | Cell Cycle Control, Apoptosis, Senescence, Angiogenesis | [116,117,118] |
| let-7 family | Breast, Colon, Gastric, Liver, Lung, Prostate, Ovarian Cancer, Chronic Myelogenous Leukemia, B Cell Lymphoma | NF2, HRAS, KRAS, NRAS, LIN28, MYC, DICER1, HMGA2, CASP3 | Oncogene Inhibition, Cell Cycle Control, Cancer Stem Cell Regulation | [72,119-124,125] |
| miR-21 | Ovarian, Lung, and Colon Carcinoma, Pancreatic and Breast Cancer | TPM1, NFIB, PDCD4, CDKN1A, FAS, TIMP3, SOX5, PTEN, BMPR2 | Promotion of Cancer Cell Proliferation, Survival and Migration | [79-83,126-128] |
| miR-17-92 cluster | Leukemia | DICER, PTEN, E2F1, E2F2, E2F3, CDKN1A, PTEN, BCL2, CCND1, BMPR2, HOXA9 | Induction of Angiogenesis, Enhance Endothelial Cell Migration | [94,129] |
| miR-494 | Small Cell Lung Carcinoma, Breast Cancer | PTEN, CDH17, MAL | Inhibition of Apoptosis, Induction of Chemoresistance, Cell Adhesion | [89,130] |
| miR-210 | Breast Cancer, Renal, Prostate, and Pancreatic Cancer, Lymphoma | MYC, STAT5A, HIF1A, TP53, E2F3, VEGFA, EGFR, CDKN1A, AKT1, DICER1, PTEN, CDKN1B, ERBB2, CD40, BCL2, CASP8AP2, KRAS, NOTCH1 | Metastasis, Angiogenesis, Hypoxia, Tumorigenesis | [7,96,131-133] |
| miR-200 family | Breast Cancer | ZEB1, ZEB2, SIP1, CCND1, CDC25C, MYC, MYCN, PTEN, SIRT1, VEGFA, MET, CDKN1B, TP53, PROM1, EGFR, CD44 | Tumorigenesis and Tumor Progression, Metastasis, Invasion | [92,93] |
| miR-9 | Melanoma, Glioblastoma, Neuroblastoma | MYC, MYCN,VEGFA, MMP9, CDH1 | Metastasis, Drug Resistance, Angiogenesis | [95,110,134,135] |
| miR-221/miR-222 | Breast, Colorectal, Renal, Pancreatic, and Ovarian Cancer, Melanoma, Glioblastoma, Leukemia | KIT, PTEN, CDKN1A, CDKN1B, KRAS, DICER1, MMP1 | Drug Resistance, Metastasis, Invasion, Cell Growth | [108,136-143] |
| miR-23b | Breast, Renal, Pancreatic, Bladder, and Prostate Cancer Thymic Lymphoma | VHL, PTEN, FAS, NISCARI, PAK2, ATG12, ZEB1, SRC, AKT | Cell Proliferation, Chemoresistance, Inhibition of Invasion and Angiogenesis | [73,75] |
| miR-542-3p | Pancreatic, and Cervical Carcinoma, Neuroblastoma, Colon Cancer | CDH17, TRAF4, ANGPT2, ILK, SURVIVIN | Decreased Cell Adhesion, Induction of Apoptosis, Inhibition of Proliferation and Angiogenesis | [89,144,145] |
| miR-125b | Breast, and Liver Cancer | LIN28B, CCND1, SOX2, MYC, CDK6, | Increase Drug Resistance, Decreased in Resistant Cells, Inhibits Cell Proliferation | [146-149] |
| miR-105 | Breast, Ovarian, Gastric, and Prostate Cancer, Glioma, Hepatocellular Carcinoma | TJP1 DNTT, PCNA, BAX, CCND1, CDK6 | Regulation of Migration, Metastasis, Proliferation, Apoptosis | [91,150-153] |
| miR-29 | Breast, Lung, and Cervical Cancer, Neuroblastoma, B Cell Chronic and Acute Myeloid Leukemia | BACE1, DNMT3A, DNMT3B, CDC42, CDK6, TGFB3, IFNG | Modulation of Immune Response, Tumor Growth and Metastasis, Tumor Suppressor Function | [85,154-156] |